Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses
H. Aoki, M. Tsunoda, H. Ogiwara, H. Shimizu, H. Abe, T. Abe, S. Shichino, K. Matsushima, S. Ueha
Abstract
The repertoire of tumor-infiltrating T cells is an emerging perspective for characterizing effective antitumor T-cell responses. Oligoclonal expansion of tumor T-cell repertoire has been evaluated; however, their association with antitumor effects is unclear. We demonstrated that the polyclonal fraction of the tumor-reactive T-cell repertoire consisting of relatively minor clones increased in tumor-bearing mice treated with anti-PD-L1 or anti-CD4 monoclonal antibody, which was correlated with antitumor effect. Meanwhile, the size of the oligoclonal fraction consisting of major clones remained unchanged. Moreover, the polyclonal fraction was enriched in progenitor exhausted T cells, which are essential for a durable antitumor response, and was more dependent on CCR7+ migratory dendritic cells, which are responsible for priming tumor-reactive T cells in the tumor-draining lymph nodes. These results suggest that the expansion of diverse tumor-reactive clones ("clonal spreading") is an important mechanism by which anti-PD-L1 and anti-CD4 treatments induce robust and durable antitumor T-cell responses.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differentiation and Expansion of Tumor-Infiltrating T Cell Clonotypes Occurs in the Spleen Following Immune Checkpoint Blockade
D. M. Morgan, B. L. Horton, … S. Spranger·bioRxiv·Sep 4, 2023
- Clonal replacement of tumor-specific T cells following PD-1 blockade
K. E. Yost, A. T. Satpathy, … H. Y. Chang·bioRxiv·May 24, 2019
- Interferon-γ driven differentiation of monocytes into PD-L1+ and MHC II+ macrophages and the frequency of Tim-3+ tumor-reactive CD8+ T cells within the tumor microenvironment predict a positive response to anti-PD-1-based therapy in tumor-bearing mice
Jelena Gabrilo, Sylvie Vande Velde, … Oberdan Léo·Cancer Immunology ResearchPeer-reviewed·Aug 28, 2025
- Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma
J. Chiffelle, D. Barras, … G. Coukos·bioRxiv·Jul 21, 2023
- Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response against the AH1 tumor rejection antigen
P. Probst, M. Stringhini, D. Neri·bioRxiv·Oct 2, 2019
- PD-1 blockade-driven anti-tumor CD8+ T cell immunity requires XCR1+ dendritic cells
T. Mao, E. Song, A. Iwasaki·bioRxiv·Apr 28, 2020